Accepted answer
On the detail: the distinction worth making early is between a tolerability problem, which is unpleasant and self-limiting, and a clinical problem, which is neither. They present differently and the thresholds for each are worth writing down before you need them.
Distinguishing an injection-site nodule from an infection: a nodule is firm, non-tender or mildly tender, not warm, not expanding, and appears within a day or two. Cellulitis is warm, tender, expanding, and often accompanied by systemic features. A sterile abscess sits between the two and is fluctuant. Warmth plus expansion plus fever is the combination that stops being a forum question.
Gastrointestinal adverse events, indicative pooled rates
| Event | Active arm | Placebo arm | Timing |
|---|
| Nausea | 40–45 % | 15–20 % | Peaks 1–2 wk after each step |
| Vomiting | 15–25 % | 5–8 % | Follows nausea |
| Diarrhoea | 20–30 % | 10–15 % | Early, variable |
| Constipation | 20–25 % | 8–12 % | Later onset, persistent |
| Discontinuation for GI events | 4–7 % | 1–2 % | Mostly during escalation |
Ranges span agents and doses; read the specific prescribing information for a specific figure.
Fatigue attribution is a subtraction problem. Take out the energy deficit, the dehydration, the electrolyte shortfall and the poor sleep, and what remains attributable to the drug in the trials was modest — placebo-arm fatigue rates were within a few points of active-arm rates in most of the programme. The corollary is that the fixable causes are usually the actual causes.
SURMOUNT-1 reported gastrointestinal events as the most frequent adverse events, mostly mild to moderate and mostly during escalation, with discontinuation for adverse events in the single digits per cent[1].
One qualification — reported incidence in a monitored trial population is a lower bound on what happens in an unmonitored one, because trial participants were escalated to protocol and supported through it.
Most of this resolves. The point of knowing the pattern is to recognise the small fraction that does not.
8Thank you — the worked example is what makes this usable. – lipid_panel_q 3 months ago Related: the same reasoning applies to the counter-ion question. – h_pergande 5 months ago add a comment